Abstract
Therapy resistance and disease recurrence are two of the most challenging aspects in breast cancer treatment. A recent article in Cancer Cell makes a significant contribution toward a better understanding of this therapeutic problem by establishing downregulation of the tumor suppressor Par-4 as the primary determinant of breast cancer recurrence. This viewpoint brings forth the importance of their findings and its implications on future research and therapy.
| Original language | English |
|---|---|
| Article number | 314 |
| Journal | Breast Cancer Research |
| Volume | 15 |
| Issue number | 5 |
| DOIs | |
| State | Published - Oct 25 2013 |
Bibliographical note
Funding Information:This work was supported by National Cancer Institute/National Institutes of Health grant CA060872 and Kentucky Lung Cancer Research grant (to VMR).
Funding
This work was supported by National Cancer Institute/National Institutes of Health grant CA060872 and Kentucky Lung Cancer Research grant (to VMR).
| Funders | Funder number |
|---|---|
| Kentucky Lung Cancer Research Association | |
| National Institutes of Health (NIH) | |
| National Childhood Cancer Registry – National Cancer Institute | R01CA060872 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
ASJC Scopus subject areas
- Oncology
- Cancer Research
Fingerprint
Dive into the research topics of 'Par-4 prevents breast cancer recurrence'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver